Psychemedics Corporation (PMD)
| Market Cap | 43.76M |
| Revenue (ttm) | 23.81M |
| Net Income (ttm) | 413,000 |
| Shares Out | 5.54M |
| EPS (ttm) | 0.07 |
| PE Ratio | 109.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,737 |
| Open | 7.64 |
| Previous Close | 7.43 |
| Day's Range | 7.58 - 7.90 |
| 52-Week Range | 4.13 - 8.90 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2021 |
About PMD
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual ...
Financial Performance
Financial StatementsNews
Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021
ACTON, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the third qu...
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second q...
5 Undervalued Stocks Trading Below the Peter Lynch Value
According to the GuruFocus All-in-One Screener, a Premium feature, as of June 28, the following companies are trading below their Peter Lynch fair values with wide margins of safety and have had positiv...
Montana Advisors Writes Open Letter to Psychemedics
MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time y...
Psychemedics Corporation Reports First Quarter 2021 Financial Results
ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first qua...
Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year fina...
Robyn C. Davis Joins Psychemedics Board of Directors
ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporati...
Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller
ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller.
Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel
ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel.
Psychemedics Announces Third Quarter Results
ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.
Psychemedics Announces Second Quarter Results
ACTON, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020.
Psychemedics Announces First Quarter Results
ACTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020.
Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA
A New and Cost-Effective Tool to Detect and Deter Nicotine use A New and Cost-Effective Tool to Detect and Deter Nicotine use
Psychemedics Corporation Responds to Court Decision
ACTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police Department v...
Psychemedics Corporation Announces New Brazilian Distribution Agreement
ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with...